Stock Market Reviews

LMAT (LeMaitre Vascular, Inc.) News

Get the latest news, insights, and market updates on LMAT (LeMaitre Vascular, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• 3 Profitable Stocks That Concern Us
  Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
  Dec 29, 2025 - $LMAT
• Reflecting On Surgical Equipment & Consumables - Specialty Stocks’ Q3 Earnings: LeMaitre (NASDAQ:LMAT)
  The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - specialty stocks fared in Q3, starting with LeMaitre (NASDAQ:LMAT).
  Dec 25, 2025 - $LMAT
• LeMaitre Vascular (NASDAQ:LMAT) Hasn't Managed To Accelerate Its Returns
  If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
  Dec 21, 2025 - $LMAT
• 1 Small-Cap Stock to Target This Week and 2 That Underwhelm
  Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
  Dec 18, 2025 - $LMAT
• 1 Cash-Heavy Stock with Impressive Fundamentals and 2 We Question
  A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
  Dec 10, 2025 - $LMAT
• Zacks.com featured highlights include Life Time, Cardinal Health, LeMaitre Vascular and Flowserve
  LTH, CAH, LMAT and FLS emerge as high-coverage-ratio standouts for investors seeking sturdier balance-sheet safety into 2026.
  Dec 2, 2025 - $LMAT
• Is LeMaitre Vascular’s Drop an Opportunity After Expansion and Regulatory News?
  Curious if LeMaitre Vascular is a bargain buy, a hidden gem, or just treading water? Let's peel back the layers and see if the stock's true value stands out in today's market. After a strong three- and five-year run, LeMaitre Vascular has cooled off lately, with the share price falling 5.7% in the past week, 4.2% over the past month, and 21.7% in the last year. Much of this recent volatility seems driven by ongoing discussions about the company's expansion in its vascular device portfolio...
  Dec 1, 2025 - $LMAT
• LeMaitre Vascular (LMAT): A Fresh Look at Valuation After Recent Share Price Weakness
  LeMaitre Vascular (LMAT) has captured investor attention recently, sparking conversations about what might be driving its stock moves. With its portfolio of vascular devices and presence across global healthcare markets, the company stands out in its niche. See our latest analysis for LeMaitre Vascular. After a challenging few months, LeMaitre Vascular’s latest share price of $82.95 places it well below previous highs, with a year-to-date share price return of -9.31% and a 1-year total...
  Nov 30, 2025 - $LMAT
• 1 Reason LMAT is Risky and 1 Stock to Buy Instead
  LeMaitre currently trades at $83.37 per share and has shown little upside over the past six months, posting a middling return of 2.9%. The stock also fell short of the S&P 500’s 15.6% gain during that period.
  Nov 28, 2025 - $LMAT
• Here is Why Growth Investors Should Buy LeMaitre (LMAT) Now
  LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
  Nov 27, 2025 - $LMAT